Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent
IGF-1 LR3 is priced at $160 per 1mg vial which provides approximately 100 individual 10mcg doses, bringing the effective cost to roughly $1.60 per dose
Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease
Concerns about pancreatitis have emerged since GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and liraglutide (Victoza) became widely prescribed for type 2 diabetes and weight management
Finally, although physical fitness was assessed using validated high-quality measures, additional functional tests such as the short physical performance battery, timed up-and-go, and handgrip strength could have provided further insights into functional domains and upper-body strength
IARC, International Agency for Research on Cancer